Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia

Novella Pugliese, MD Graduate student, Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Laura Cella, PhD, Santa Errichiello, PhD, Luana Marano, Simona Caruso, Graduate student, Nicola Esposito, Barbara Izzo, PhD, Marco Picardi, MD, Vincenzo Martinelli, MD, Fabrizio Pane, MD

Blood (2014) 124 (21): 1850.

https://doi.org/10.1182/blood.V124.21.1850.1850

Published: 2014

Journal Articles

The Interferon Score Towards Interferon Alpha Tailored Therapy In Essential Thrombocythemia

Novella Pugliese, MD, Novella Pugliese, MD, Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Luana Marano, Santa Errichiello, PhD, Nicola Esposito, Maddalena Raia, Claudio Cerchione, Luigi Del Vecchio, MD, Marco Picardi, MD, Vincenzo Martinelli, MD, Fabrizio Pane

Blood (2013) 122 (21): 4073.

https://doi.org/10.1182/blood.V122.21.4073.4073

Published: 2013

Journal Articles

Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib.

Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Santa Errichiello, PhD, Simona Caruso, Nicola Esposito, PhD, Luigia Luciano, MD, Simona Paratore, PhD, Claudia Galimberti, PhD, Simona Soverini, PhD, Carolina Terragna, PhD, Daniela Cilloni, MD, Giuseppe Saglio, MD, Giovanni Martinelli, Frank Giles, MD, Andreas Hochhaus, MD, Fabrizio Pane

Blood (2012) 120 (21): 2795.

https://doi.org/10.1182/blood.V120.21.2795.2795

Published: 2012

Journal Articles

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Blood (2011) 118 (13): 3634–3644.

https://doi.org/10.1182/blood-2011-03-341073

Published: 2011

Includes: Supplemental data

Journal Articles

Preferential nuclear accumulation of JAK2V617F in CD34 + but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia

Ciro R. Rinaldi, Paola Rinaldi, Adele Alagia, Marica Gemei, Nicola Esposito, Fabio Formiggini, Vincenzo Martinelli, Vitalyi Senyuk, Giuseppina Nucifora, Fabrizio Pane

Blood (2010) 116 (26): 6023–6026.

https://doi.org/10.1182/blood-2010-08-302265

Published: 2010

Journal Articles

Preferential Nuclear Accumulation of JAK2V617F In CD34+ but Not Granulocytic, Megakaryocytic or Erythroid Cells of Patients with Philadelphia-Negative Myeloproliferative Neoplasia

Ciro R Rinaldi, MD, Paola Rinaldi, Adele Alagia, Marica Gemei, Vitalyi Senyuk, PhD, Nicola Esposito, Fabio Formiggini, Vincenzo Martinelli, Anthony R. Green, PhD, FRCP, FRCPath, Giuseppina Nucifora, Fabrizio Pane, MD

Blood (2010) 116 (21): 4089.

https://doi.org/10.1182/blood.V116.21.4089.4089

Published: 2010

Journal Articles

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

Blood (2009) 114 (22): 2212.

https://doi.org/10.1182/blood.V114.22.2212.2212

Published: 2009

Journal Articles

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

Nicola Esposito, PhD, Fabrizio Quarantelli, Luigia Luciano, MD, Barbara Izzo, PhD, Anna Lucia Peluso, PhD, Marco Picardi, MD, Susan Branford, PhD, D.L. White, PhD, Timothy Hughes, PhD, Jerald Radich, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giuseppe Saglio, MD, Thea Kalebic, PhD, Mark Thornquist, PhD, Giovanni Martinelli, MD, Fabrizio Pane, MD

Blood (2008) 112 (11): 1106.

https://doi.org/10.1182/blood.V112.11.1106.1106

Published: 2008

Journal Articles

A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment

Nicola Esposito, PhD, Irene Colavita, PhD, Fabrizio Quarantelli, PhD, Barbara Izzo, PhD, Luigia Luciano, MD, Luigi Del Vecchio, MD, Timothy Hughes, Jerald Radich, Domenico Russo, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Junia Melo, MD, PhD, Margherita Ruoppolo, PhD, Thea Kalebic, Fabrizio Pane, MD

Blood (2008) 112 (11): 3186.

https://doi.org/10.1182/blood.V112.11.3186.3186

Published: 2008

Journal Articles

Expression Profiling of ABC Transporter Genes in Chronic Myeloid Leukemia (CML) and Responsiveness to Imatinib

Nunzio Iraci, Simona Soverini, Samuele Gherardi, Emanuele Valli, Fausto Castagnetti, Roberto Bernardoni, Gianantonio Rosti, Giuliano Della Valle, Francesca Palandri, Gabriele Gugliotta, Fabrizio Pane, Giuseppe Saglio, Nicola Esposito, Daniela Cilloni, Fabrizio Quarantelli, Enrico Gottardi, Michele Baccarani, Giovanni Martinelli, Giovanni Perini

Blood (2008) 112 (11): 3193.

https://doi.org/10.1182/blood.V112.11.3193.3193

Published: 2008

Journal Articles

Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment.

Nicola Esposito, PhD, Fabrizio Quarantelli, PhD, Barbara Izzo, PhD, Giada Muccioli Casadei, MD, Luigia Luciano, MD, Giuseppe Saglio, MD, Junia V. Melo, MD, Thea Kalebic, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD

Blood (2007) 110 (11): 1014.

https://doi.org/10.1182/blood.V110.11.1014.1014

Published: 2007

NARROW

A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia

The Interferon Score Towards Interferon Alpha Tailored Therapy In Essential Thrombocythemia

Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib.

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Preferential nuclear accumulation of JAK2V617F in CD34 + but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia

Preferential Nuclear Accumulation of JAK2V617F In CD34+ but Not Granulocytic, Megakaryocytic or Erythroid Cells of Patients with Philadelphia-Negative Myeloproliferative Neoplasia

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment

Expression Profiling of ABC Transporter Genes in Chronic Myeloid Leukemia (CML) and Responsiveness to Imatinib

Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only